In addition, tumor samples were collected, and a significant decrease in CD8 + T cells and an increase in MDSCs were observed in the tumor sites treated with GL261-sEVs, while fewer tumor-infiltrating CD8 + T lymphocytes and more MDSCs were observed in the tumor sites treated with GL261-pirb-sEVs than in those treated with GL261-sEVs (Fig. 6D). The gene discussed is CD8A; the disease is neoplasm.